Company Name
BioLineRx Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US09071M3043
CIK:
0001498403
CUSIP:
09071M205
Currency:
USD
Full Time Employees:
28
Phone:
972 8 642 9100
Website:
https://www.biolinerx.com
Fiscal Year End:
December
IPO Date:
Jul 25, 2011
Description:
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Address:
Modi?in Technology Park, Hevel Modi'in, Israel, 7177871